- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06830590
Study of Molecular Characterisation of Early Operable Primary Breast Cancer in Pakistani Population (BrCa)
August 7, 2025 updated by: Prof. Binafsha Manzoor Syed, Liaquat University of Medical & Health Sciences
This study is looking at the biological characteristics of early operable primary breast cancer in Pakistani Population by using IHC
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Binafsha Manzoor M Syed, MBBS, PhD
- Phone Number: +923332749201
- Email: Binafsha.syed@lumhs.edu.pk
Study Locations
-
-
-
Jamshoro, Pakistan
- Recruiting
- Binafsha M Syed
-
Contact:
- Binafsha M Syed
- Phone Number: 03332749201
- Email: drbinafsha@hotmail.com
-
Contact:
- Email: drbinafsha@hotmail.com
-
Principal Investigator:
- Binafsha M Syed, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The population are women with early operable primary breast cancer underwent surgery without any prior treatment.
Description
Inclusion Criteria:
- Women with confirmed diagnosis of breast cancer without history of taking neoadjuvant therapy Good quality tumour samples available for IHC
Exclusion Criteria:
- patients received pre-operative chemotherapy or radiotherapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Early operable primary breast cancer
|
All patients treated by surgery were included without any neoadjuvant therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Breast cancer specific survival in correlation with molecular pattern
Time Frame: 10 years
|
10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Binafsha Manzoor M Syed, MBBS, PhD, Liaquat University of Medical & Health Sciences, Jamshoro
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2016
Primary Completion (Estimated)
December 30, 2025
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
February 11, 2025
First Submitted That Met QC Criteria
February 11, 2025
First Posted (Actual)
February 17, 2025
Study Record Updates
Last Update Posted (Actual)
August 13, 2025
Last Update Submitted That Met QC Criteria
August 7, 2025
Last Verified
August 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BreastCa001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
data will be shared in the form of overall results with pattern of biomarkers.
Individual participants data will not be shared
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
Clinical Trials on Molecular characterisation
-
Ludwig-Maximilians - University of MunichUniversity of LuxembourgCompletedIschemic Stroke | Transient Ischemic AttackGermany
-
University of BirminghamFederico II University; Brigham and Women's Hospital; University of Erlangen-Nürnberg and other collaboratorsUnknown
-
University Hospital, RouenRecruitingPatients With Chronic Pruritus for More Than 1 Month Who Have Received ImmunotherapyFrance
-
Royal Marsden NHS Foundation TrustRecruiting
-
Gdansk University of Physical Education and SportMedical University of Gdansk; Kazimierz Wielki UniversityNot yet recruitingSport Performance | Aerobic Capacity | Sport Recovery | Physiological Adaptations | Anaerobic PowerPoland
-
Belarusian State Medical UniversityThe Institute of Genetics and Cytology National Academy of Sciences of Belarus and other collaboratorsNot yet recruitingThyroid Cancer | Thyroid Nodule
-
Institut Paoli-CalmettesTerminated
-
Istituto Ortopedico RizzoliIstituto Nazionale Tumori IRCCS - Fondazione G. Pascale; Azienda Ospedaliera... and other collaboratorsActive, not recruiting
-
University Health Network, TorontoCompletedCarcinoma, Pancreatic DuctalCanada
-
Children's Hospital of Fudan UniversityBoston Children's Hospital; First Affiliated Hospital, Sun Yat-Sen University; Tongji Hospital and other collaboratorsCompleted